<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01130077</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY19040319</org_study_id>
    <secondary_id>PRO08030085</secondary_id>
    <nct_id>NCT01130077</nct_id>
    <nct_alias>NCT00862199</nct_alias>
  </id_info>
  <brief_title>A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction With Poly-ICLC in Pediatric Gliomas</brief_title>
  <official_title>A Pilot Study to Evaluate the Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides With Poly-ICLC for Children With Newly Diagnosed Malignant Brain Stem Gliomas, Non-Brainstem High-Grade Gliomas, Recurrent Low-Grade Gliomas or Recurrent High Grade Gliomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ian F. Pollack, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ellie Kavalieros Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Translational Brain Tumor Research Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Connor's Cure</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective of this pilot study is to collect immunological and safety data&#xD;
      following administration of vaccinations with HLA-A2. This data will be used to decide&#xD;
      whether a larger study of clinical efficacy is warranted.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Pilot study to assess tolerability of this vaccine regimen in different strata of children with high risk gliomas</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Tolerability during the first two vaccine courses as defined in the protocol.</measure>
    <time_frame>6 weeks</time_frame>
    <description>Tolerability during the first two vaccine courses as defined in the protocol.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glioma-associated antigen-specific T-cell response</measure>
    <time_frame>Monitoring will continue as long as subject remains on study.</time_frame>
    <description>Glioma-associated antigen-specific T-cell response: determined by IFN-gamma-enzyme linked immune spot (ELISPOT) and tetramer assays</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Newly Diagnosed Pediatric Pontine Glioma</condition>
  <condition>Newly Diagnosed Pediatric High Grade Glioma</condition>
  <condition>Recurrent Pediatric High Grade Glioma</condition>
  <condition>Recurrent Pediatric Low Grade Glioma</condition>
  <arm_group>
    <arm_group_label>HLA Restricted glioma antigen peptides plus Poly ICLC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive vaccine plus Poly ICLC will receive 9 injections ( once every 3 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HLA-A2 restricted glioma antigen peptides vaccine</intervention_name>
    <description>Vaccine given every 3 weeks</description>
    <arm_group_label>HLA Restricted glioma antigen peptides plus Poly ICLC</arm_group_label>
    <other_name>BB13624</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Poly-ICLC</intervention_name>
    <description>Vaccine given every 3 weeks</description>
    <arm_group_label>HLA Restricted glioma antigen peptides plus Poly ICLC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        **Inclusion Criteria&#xD;
&#xD;
        *Tumor Types - Tumor type/location:&#xD;
&#xD;
        Stratum A: Newly diagnosed diffuse intrinsic pontine gliomas OR any biopsy proven&#xD;
        high-grade glioma* involving the brainstem. Patients may not have received chemotherapy&#xD;
        during or after radiation. (Note: Stratum A is closed to accrual.)&#xD;
&#xD;
        Stratum B: Newly diagnosed, non-brainstem high-grade glioma* Patients may not have received&#xD;
        chemotherapy during or after radiation. (Note: Stratum B is open to accrual.)&#xD;
&#xD;
        Stratum C: Unresectable low-grade gliomas that have received at least two&#xD;
        chemotherapy/biologic regimens. Patients may not have received radiation to the index&#xD;
        lesion within 1 year of enrollment. (Note: Stratum C is closed to accrual.)&#xD;
&#xD;
        Stratum D: Non-brainstem high-grade gliomas* that have recurred following treatment. (Note:&#xD;
        Stratum D is closed to accrual.)&#xD;
&#xD;
        Stratum E: Newly diagnosed high-grade gliomas* or brain stem gliomas who received&#xD;
        chemotherapy during radiation therapy. Patients may not have received chemotherapy after&#xD;
        radiation therapy was completed. (Note: Stratum E is closed to accrual.)&#xD;
&#xD;
        Stratum F: Newly diagnosed high-grade gliomas with metastatic disease within the CNS&#xD;
        requiring craniospinal radiation therapy. Patients may or may not have received&#xD;
        chemotherapy during radiation, but cannot have received chemotherapy after radiation&#xD;
        therapy was completed. (Note: Stratum F is closed to accrual.)&#xD;
&#xD;
          -  Eligible histologies include glioblastoma (GBM), anaplastic astrocytoma (AA) or&#xD;
             gliosarcoma. Patients with any oligodendroglioma component are NOT eligible.&#xD;
&#xD;
          -  HLA-A2 positive based on flow cytometry.&#xD;
&#xD;
          -  Patients in Stratum A B and E must have received standard involved field radiation&#xD;
             therapy [RT] defined as fractionated external beam radiotherapy with total doses&#xD;
             between 5000-6000 cGy. Patients in these strata must be registered within 4-12 weeks&#xD;
             of completing RT.&#xD;
&#xD;
          -  Patients in Stratum F must have received craniospinal radiation.&#xD;
&#xD;
          -  Patients must be clinically stable and off or on low-dose (no more than 0.1 mg/kg/day,&#xD;
             max 4 mg/day Dexamethasone) corticosteroid for at least one week prior to study&#xD;
             registration.&#xD;
&#xD;
          -  All patients must sign an IRB-approved informed consent document&#xD;
&#xD;
          -  Patients must be ≥ 12 months and &lt;22 years of age at the time of study registration.&#xD;
&#xD;
          -  Patients must have a performance status of ≥ to 60.&#xD;
&#xD;
          -  Patients must have life expectancy of at least 8 weeks.&#xD;
&#xD;
          -  Documented negative serum βHCG for female patients who are post-menarchal. Pregnant&#xD;
             females will not be included in the study. Males and females must agree to use&#xD;
             effective birth control methods during the course of vaccination.&#xD;
&#xD;
          -  Patients must be free of systemic infection.&#xD;
&#xD;
          -  Patients with adequate organ function as measured by: Bone marrow: ANC &gt; 1,000/µl;&#xD;
             Platelets &gt; 100,000/µl (transfusion independent); absolute lymphocyte count of&#xD;
             ≥500/uL; Hemoglobin &gt;8 g/dl (may be transfused). Hepatic: bilirubin ≤ 1.5x&#xD;
             institutional normal for age; SGPT (ALT) &lt; 3x institutional normal.&#xD;
&#xD;
        Renal: Serum creatinine based on age or Creatinine clearance or radioisotope GFR &gt;70&#xD;
        ml/min/ml/min/1.73 m²&#xD;
&#xD;
          -  Patients on Strata C and D must have recovered from the toxic effects of prior&#xD;
             therapy: at least 3 weeks form the last dose of standard cytotoxic chemotherapy or&#xD;
             myelosuppressive biological therapy and at least 1 week from the last dose of&#xD;
             non-myelosuppressive biologic therapy.&#xD;
&#xD;
          -  No overt cardiac, gastrointestinal, pulmonary or psychiatric disease.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients living outside of North America are not eligible.&#xD;
&#xD;
        Presence of metastatic disease for patients in Stratum A, B, D and E. Patients with low&#xD;
        grade gliomas (stratum C) may have tumor spread within the CNS.&#xD;
&#xD;
        Patients in Stratum F must have tumor spread within the CNS.&#xD;
&#xD;
        Patients enrolled in Strata A and B may not have received any prior chemotherapy or&#xD;
        anti-glioma therapy of any type other than radiation therapy. Patients enrolled on stratum&#xD;
        C must have received at least two prior chemotherapy or biologic therapy regimens and may&#xD;
        not have received radiation to the index lesion within 1 year of enrollment. Patients on&#xD;
        Strata A, B, E, and F can not have received chemotherapy after radiation therapy was&#xD;
        completed.&#xD;
&#xD;
        Concurrent treatment or medications (must be off for at least 1 week) including:&#xD;
&#xD;
          -  Interferon (e.g. Intron-A®)&#xD;
&#xD;
          -  Allergy desensitization injections&#xD;
&#xD;
          -  Growth factors (e.g. Procrit®, Aranesp®, Neulasta®)&#xD;
&#xD;
          -  Interleukins (e.g. Proleukin®)&#xD;
&#xD;
          -  Any investigational therapeutic medication&#xD;
&#xD;
        Patients must not have a history of, or currently active autoimmune disorders.&#xD;
&#xD;
        Use of immunosuppressives within four weeks prior to study entry. Dexamethasone, or other&#xD;
        corticosteroid medications, if used in the peri-operative period and/or during&#xD;
        radiotherapy, must be tapered (no more than 0.1 mg/kg/day, max 4 mg/day dexamethasone) for&#xD;
        at least one week before study registration. Topical corticosteroids are acceptable.&#xD;
&#xD;
        Patients with known addiction to alcohol or illicit drugs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alberto Broniscer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 24, 2010</study_first_submitted>
  <study_first_submitted_qc>May 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2010</study_first_posted>
  <last_update_submitted>August 3, 2021</last_update_submitted>
  <last_update_submitted_qc>August 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Ian F. Pollack, M.D.</investigator_full_name>
    <investigator_title>Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Pediatric glioma</keyword>
  <keyword>Vaccine therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Poly ICLC</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

